Merck Licenses Experimental Psoriasis Drug to Sun Pharma

Merck & Co Inc said it has licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million (Rs 480 crore at 1 dollar = 60 rupees).

Under the agreement, Sun Pharma will acquire the worldwide rights to the drug, tildrakizumab, for all possible indications.

The drug is currently in late-stage trials for use in chronic plaque psoriasis, an inflammatory skin disease.

Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including manufacturing and marketing the approved product, the companies said.

Merck's shares were down about 1 per cent at $59.41 on the New York Stock Exchange on Wednesday. Shares in Sun Pharmaceutical ended at Rs 792.40 on National Stock Exchange.

Copyright @ Thomson Reuters 2014

Unlock this article for free
Sign up to access exclusive stories, fewer ads, and a personalised experience.
Set as Trusted Source
on Google Search